Loading...
•
Dec 31, 2022
Vanda Q4 2022 Earnings Report
Reported a decrease in total revenues and net income compared to the same quarter last year, while making progress on regulatory filings and intellectual property litigation.
Key Takeaways
Vanda Pharmaceuticals reported Q4 2022 total revenues of $64.5 million, a 5% decrease compared to Q4 2021. Net income was $6.9 million, slightly lower than the $7.1 million reported in the same quarter of the previous year. The company is pursuing regulatory approvals for HETLIOZ® and preparing for an NDA submission for tradipitant.
Total revenues for Q4 2022 were $64.5 million, a 5% decrease year-over-year.
HETLIOZ® net product sales decreased by 9% to $40.1 million due to reimbursement challenges.
Fanapt® net product sales increased by 2% to $24.4 million.
Net income was $6.9 million, slightly lower compared to $7.1 million in Q4 2021.
Revenue by Segment
Forward Guidance
Due to uncertainties surrounding the U.S. market for HETLIOZ® as a result of the ongoing HETLIOZ® patent litigation, Vanda is unable to provide 2023 financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...